XML 52 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1

Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2023

Revenue Recognition [Abstract]

Schedule of Disaggregated Revenue

Segment Net Sales
MedSurg and Neurotechnology:			2023						2022						2021
Instruments			$	2,569					$	2,279					$	2,111
Endoscopy			3,033						2,725						2,418
Medical			3,459						3,031						2,607
Neurovascular			1,226						1,200						1,188
Neuro Cranial			1,549						1,376						1,214
			$	11,836					$	10,611					$	9,538
Orthopaedics and Spine:
Knees			$	2,273					$	1,997					$	1,848
Hips			1,544						1,413						1,342
Trauma and Extremities			3,147						2,807						2,664
Spine			1,189						1,146						1,167
Other			509						475						549
			$	8,662					$	7,838					$	7,570
Total			$	20,498					$	18,449					$	17,108

United States Net Sales
MedSurg and Neurotechnology:			2023						2022						2021
Instruments			$	2,051					$	1,810					$	1,637
Endoscopy			2,478						2,211						1,943
Medical			2,785						2,422						2,007
Neurovascular			483						446						451
Neuro Cranial			1,270						1,135						988
			$	9,067					$	8,024					$	7,026
Orthopaedics and Spine:
Knees			$	1,676					$	1,493					$	1,351
Hips			988						896						822
Trauma and Extremities			2,297						2,035						1,866
Spine			883						836						831
Other			346						354						425
			$	6,190					$	5,614					$	5,295
Total			$	15,257					$	13,638					$	12,321

International Net Sales
MedSurg and Neurotechnology:			2023						2022						2021
Instruments			$	518					$	469					$	474
Endoscopy			555						514						475
Medical			674						609						600
Neurovascular			743						754						737
Neuro Cranial			279						241						226
			$	2,769					$	2,587					$	2,512
Orthopaedics and Spine:
Knees			$	597					$	504					$	497
Hips			556						517						520
Trauma and Extremities			850						772						798
Spine			306						310						336
Other			163						121						124
			$	2,472					$	2,224					$	2,275
Total			$	5,241					$	4,811					$	4,787

Changes in Contract Liabilities

Changes in contract liabilities during the year were as follows:

			2023
Beginning contract liabilities			$	741
Revenue recognized from beginning of year contract liabilities			(379)
Net advance consideration received during the period			498
Ending contract liabilities			$	860

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueRecognitionAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration